A comprehensive review finds that GLP-1 receptor agonists, popular diabetes medications, show varying effects on cancer risk - protective against some cancers while potentially increasing risk for others. The findings emphasize the need for personalized treatment approaches.

This review elucidates the specific roles of the above mechanisms in the development of obesity-associated cancers at different sites, and outline intervention strategies to prevent obesity-associated cancers.

This review elucidates the dysfunction of B cells in tumor microenvironment, summarizes the discovery and mechanism of action of B cell ICs in tumors, and discusses urgent issues and future perspectives.

Researchers review controversial effects of fecal microbiota transplantation (FMT) on immune checkpoint inhibitor therapy. While some studies show improved cancer outcomes, others reveal no benefit or adverse effects, highlighting the complex relationship between gut bacteria and cancer treatment success.

Researchers discovered immune checkpoint inhibitors (ICIs)—revolutionary cancer drugs—significantly increase the risk of cholestasis, a rare bile buildup that damages the liver. Younger patients (<65) and those receiving anti-PD-1 drugs face higher risk. Women develop symptoms earlier than men. Rigorous liver monitoring is urged.